Maxim Group analyst Anthony Vendetti maintained a Buy rating on Zivo Bioscience (ZIVO – Research Report) yesterday. The company’s shares closed last Monday at $8.00.
Vendetti covers the Healthcare sector, focusing on stocks such as Lucid Diagnostics, Zivo Bioscience, and Moolec Science. According to TipRanks, Vendetti has an average return of -6.6% and a 32.19% success rate on recommended stocks.
The analyst consensus on Zivo Bioscience is currently a Moderate Buy rating.
Based on Zivo Bioscience’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $11.8 thousand and a GAAP net loss of $1.82 million. In comparison, last year the company had a GAAP net loss of $2 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zivo Bioscience (ZIVO) Company Description:
Zivo Bioscience, Inc. is engages in the study, development and commercialization of natural nutritional compounds and bioactive molecules from its proprietary algal strains. The company was founded by Howard R. Baer on March 28, 1983 and is headquartered in Keego Harbor, MI.
Read More on ZIVO:
